Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
2.870
-0.070 (-2.38%)
At close: Sep 4, 2025, 4:00 PM
2.910
+0.040 (1.39%)
After-hours: Sep 4, 2025, 7:12 PM EDT
Onconetix Employees
Onconetix had 5 employees as of December 31, 2024. The number of employees decreased by 7 or -58.33% compared to the previous year.
Employees
5
Change (1Y)
-7
Growth (1Y)
-58.33%
Revenue / Employee
$265,392
Profits / Employee
-$8,878,096
Market Cap
4.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | -7 | -58.33% |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | 7 | 140.00% |
| Dec 31, 2021 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ONCO News
- 7 weeks ago - Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement - GlobeNewsWire
- 2 months ago - Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire
- 3 months ago - Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - GlobeNewsWire
- 3 months ago - Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewsWire
- 3 months ago - Onco-Innovations Uplists to Cboe Canada - Business Wire
- 5 months ago - Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewsWire
- 6 months ago - Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress - GlobeNewsWire
- 9 months ago - Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing - GlobeNewsWire